Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecast
REGN analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.18 / 5 from 28 analysts
- Price target
- $863.93 average of analyst targets
- Upside to target
- +9.3% from the latest close
- Next earnings
- October 30, 2026 EPS estimate $13.58
- 52-week range
- $575.69 – $852.03
REGN analyst ratings
28 analystsNumber of analysts at each rating.
REGN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
REGN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $16.06 | $14.78 | $17.68 | $11.83 | +35.8% | 23 |
| Current fiscal year (2026) | $57.84 | $43.42 | $64.60 | $44.31 | +30.5% | 28 |
| Next fiscal year (2027) | $51.03 | $42.52 | $57.25 | $45.79 | +11.5% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
REGN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.54B | $4.35B | $4.73B | +21.0% | 21 |
| Current fiscal year (2026) | $17.46B | $15.01B | $18.39B | +21.7% | 26 |
| Next fiscal year (2027) | $18.60B | $16.42B | $20.25B | +6.5% | 23 |
REGN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
REGN revenue: reported and forecast
REGN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $13.12 | $16.05 | $15.95 | $16.03 | $16.06 | +22.5% | 3 up · 2 down |
| Current fiscal year (2026) | $45.94 | $53.22 | $53.80 | $56.52 | $57.84 | +25.9% | 9 up · 1 down |
| Next fiscal year (2027) | $47.72 | $50.40 | $50.38 | $50.63 | $51.03 | +6.9% | 5 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
REGN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; REGN beat in 10 of 12.
What analysts expect from REGN
28 analysts cover Regeneron; their consensus rating is buy (4.18 on a 1–5 scale, where 5 is a strong buy). The average price target is $863.93, 9.3% above the latest close of $790.74. Analysts expect earnings of $57.84 per share for 2026, +30.5% from a year earlier. For 2027 the average estimate is $51.03 per share on revenue of $18.6 billion. Regeneron beat the EPS estimate in 10 of the last 12 quarters.
Related: REGN income statement, REGN key metrics, REGN chart. See the REGN stock overview for the latest quote and news.
REGN forecast FAQ
What is Regeneron's price target?
The average analyst price target for Regeneron is $863.93, 9.3% above the latest close of $790.74.
Is Regeneron a buy, hold or sell?
Of 28 analysts covering Regeneron, 15 rate it a strong buy, 4 a buy, 8 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Regeneron's EPS forecast?
Analysts forecast $57.84 per share for 2026 (range $43.42 to $64.60); for 2027 the estimate is $51.03.
What is Regeneron's revenue forecast?
The average revenue estimate for 2026 is $17.5 billion, growth of 21.7%; for 2027 it is $18.6 billion.
When does Regeneron report earnings?
Regeneron is expected to report results for the quarter ending September 30, 2026 on October 30, 2026 before the market opens; the EPS estimate is $13.58.
Does Regeneron usually beat earnings estimates?
Regeneron reported EPS at or above the analyst estimate in 10 of the last 12 quarters.